How is Acquired von Willebrand Syndrome Treated?

Published: Aug 01, 2024

Treating acquired von Willebrand syndrome (AVWS) involves a multi-faceted approach that targets both the symptoms and the underlying causes. Let's explore the treatment options available for managing AVWS effectively.

Addressing the Underlying Cause

Treating AVWS often begins with managing the underlying condition responsible for the reduced VWF levels. This could involve immunosuppressive therapy for autoimmune disorders, surgical interventions for cardiovascular conditions, or chemotherapy for certain cancers. By targeting the root cause, VWF levels may normalize, reducing the bleeding risk.

Therapies to Control Bleeding

For acute bleeding episodes, treatments like DDAVP (desmopressin) and VWF concentrates are commonly used. DDAVP helps release stored VWF, while concentrates provide the missing factor directly. Antifibrinolytic agents can also be used to stabilize clots, particularly for mucosal bleeding.

Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by reduced levels of von Willebrand factor (VWF) due to underlying conditions such as autoimmune disorders, cardiovascular issues, or cancers.

Role of IVIG and Immunosuppression

In cases where autoantibodies to VWF are present, intravenous immune globulin (IVIG) may be beneficial. IVIG helps reduce antibody levels, thereby improving VWF function. Immunosuppressive therapy can also be considered to decrease antibody production, especially in patients with associated autoimmune conditions.

Frequently Asked Questions

Bleeding is treated with DDAVP, VWF concentrates, or antifibrinolytic agents.

Yes, addressing the underlying condition can help manage AVWS.

Yes, immunotherapy can help in cases with autoantibodies to VWF.

Key Takeaways

Effective management of AVWS requires a personalized treatment plan addressing both symptoms and causes.

Discuss with Doctronic to explore the best treatment options for AVWS.

Related Articles

References

Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82:368.

Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:345.

Always discuss health information with your healthcare provider.